Mitochondrial carrier homolog 2 is necessary for AML survival

HEMATOPOIESIS AND STEM CELLS| JULY 2, 2020

Mitochondrial carrier homolog 2 is necessary for AML survival

Dilshad H. Khan, Michael Mullokandov, Yan Wu, Veronique Voisin, Marcela Gronda, Rose Hurren, Xiaoming Wang, Neil MacLean, Danny V. Jeyaraju, Yulia Jitkova, G. Wei Xu, Rob Laister, Ayesh Seneviratne, Zachary M. Blatman, Troy Ketela, Gary D. Bader, Sajid A. Marhon, Daniel D. De Carvalho, Mark D. Minden, Atan Gross, Aaron D. Schimmer

Blood (2020) 136 (1): 81–92.

https://doi.org/10.1182/blood.2019000106

Key Points

Inhibiting MTCH2 increased levels of pyruvate and PDH in nucleus leading to differentiation and loss of engraftment potential in AML.

Defined a new mechanism by which mitochondrial pathways control epigenetics and differentiation in AML.

Abstract

Through a clustered regularly insterspaced short palindromic repeats (CRISPR) screen to identify mitochondrial genes necessary for the growth of acute myeloid leukemia (AML) cells, we identified the mitochondrial outer membrane protein mitochondrial carrier homolog 2 (MTCH2). In AML, knockdown of MTCH2 decreased growth, reduced engraftment potential of stem cells, and induced differentiation. Inhibiting MTCH2 in AML cells increased nuclear pyruvate and pyruvate dehydrogenase (PDH), which induced histone acetylation and subsequently promoted the differentiation of AML cells. Thus, we have defined a new mechanism by which mitochondria and metabolism regulate AML stem cells and gene expression.

Subjects:

Hematopoiesis and Stem Cells

Topics:

histone acetylation, mitochondria, pyruvates, leukemia, myelocytic, acute, genes, stem cells, metabolism, crispr

REFERENCES

1.Ohashi H, Ichikawa A, Takagi N, et al. Remission induction of acute promyelocytic leukemia by all-trans-retinoic acid: molecular evidence of restoration of normal hematopoiesis after differentiation and subsequent extinction of leukemic clone. Leukemia. 1992;6(8):859-862.

2.Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013;340(6132):622-626.

3.Zaltsman Y, Shachnai L, Yivgi-Ohana N, et al. MTCH2/MIMP is a major facilitator of tBID recruitment to mitochondria. Nat Cell Biol. 2010;12(6):553-562.

4.Grinberg M, Schwarz M, Zaltsman Y, et al. Mitochondrial carrier homolog 2 is a target of tBID in cells signaled to die by tumor necrosis factor alpha. Mol Cell Biol. 2005;25(11):4579-4590.

5.Shamas-Din A, Bindner S, Zhu W, et al. tBid undergoes multiple conformational changes at the membrane required for Bax activation. J Biol Chem. 2013;288(30):22111-22127.

6.Willer CJ, Speliotes EK, Loos RJ, et al; Genetic Investigation of ANthropometric Traits Consortium. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet. 2009;41(1):25-34.

7.Renström F, Payne F, Nordström A, et al; GIANT Consortium. Replication and extension of genome-wide association study results for obesity in 4923 adults from northern Sweden. Hum Mol Genet. 2009;18(8):1489-1496.

8.Bauer F, Elbers CC, Adan RA, et al. Obesity genes identified in genome-wide association studies are associated with adiposity measures and potentially with nutrient-specific food preference. Am J Clin Nutr. 2009;90(4):951-959.

9.Zhao J, Bradfield JP, Li M, et al. The role of obesity-associated loci identified in genome-wide association studies in the determination of pediatric BMI. Obesity (Silver Spring). 2009;17(12):2254-2257.

10.Kilpeläinen TO, den Hoed M, Ong KK, et al; Early Growth Genetics Consortium. Obesity-susceptibility loci have a limited influence on birth weight: a meta-analysis of up to 28,219 individuals. Am J Clin Nutr. 2011;93(4):851-860.

11.Katz C, Zaltsman-Amir Y, Mostizky Y, Kollet N, Gross A, Friedler A. Molecular basis of the interaction between proapoptotic truncated BID (tBID) protein and mitochondrial carrier homologue 2 (MTCH2) protein: key players in mitochondrial death pathway. J Biol Chem. 2012;287(18):15016-15023.

12.Buzaglo-Azriel L, Kuperman Y, Tsoory M, et al. Loss of muscle MTCH2 increases whole-body energy utilization and protects from diet-induced obesity [published correction appears in Cell Rep. 2017;18(5):1335-1336]. Cell Rep. 2016;14(7):1602-1610.

13.Maryanovich M, Zaltsman Y, Ruggiero A, et al. An MTCH2 pathway repressing mitochondria metabolism regulates haematopoietic stem cell fate. Nat Commun. 2015;6(1):7901.

14.Bahat A, Goldman A, Zaltsman Y, et al. MTCH2-mediated mitochondrial fusion drives exit from naïve pluripotency in embryonic stem cells. Nat Commun. 2018;9(1):5132.

15.Warner JK, Wang JC, Takenaka K, et al. Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. Leukemia. 2005;19(10):1794-1805.

16.Hart T, Chandrashekhar M, Aregger M, et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell. 2015;163(6):1515-1526.

17.Li W, Xu H, Xiao T, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 2014;15(12):554.

18.Moffat J, Grueneberg DA, Yang X, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 2006;124(6):1283-1298.

19.Chadee DN, Hendzel MJ, Tylipski CP, et al. Increased Ser-10 phosphorylation of histone H3 in mitogen-stimulated and oncogene-transformed mouse fibroblasts. J Biol Chem. 1999;274(35):24914-24920.

20.Drobic B, Pérez-Cadahía B, Yu J, Kung SK, Davie JR. Promoter chromatin remodeling of immediate-early genes is mediated through H3 phosphorylation at either serine 28 or 10 by the MSK1 multi-protein complex. Nucleic Acids Res. 2010;38(10):3196-3208.

21.Skrtić M, Sriskanthadevan S, Jhas B, et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell. 2011;20(5):674-688.

22.Novershtern N, Subramanian A, Lawton LN, et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell. 2011;144(2):296-309.

23.Ng SW, Mitchell A, Kennedy JA, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540(7633):433-437.

24.Shlush LI, Mitchell A, Heisler L, et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature. 2017;547(7661):104-108.

25.Sykes DB, Kfoury YS, Mercier FE, et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell. 2016;167(1):171-186.

26.Lechman ER, Gentner B, Ng SWK, et al. miR-126 regulates distinct self-renewal outcomes in normal and malignant hematopoietic stem cells. Cancer Cell. 2016;29(4):602-606.

27.Bowers EM, Yan G, Mukherjee C, et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol. 2010;17(5):471-482.

28.Barski A, Cuddapah S, Cui K, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007;129(4):823-837.

29.Heintzman ND, Hon GC, Hawkins RD, et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature. 2009;459(7243):108-112.

30.Sutendra G, Kinnaird A, Dromparis P, et al. A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation. Cell. 2014;158(1):84-97.

31.Brailsford MA, Thompson AG, Kaderbhai N, Beechey RB. Pyruvate metabolism in castor-bean mitochondria. Biochem J. 1986;239(2):355-361.

© 2020 by The American Society of Hematology

This program is developed by Focus Insight with the permission of American Society of Hematology, Inc. The content are excerpted from the journal Blood. Copyright © 2019 The American Society of Hematology. All rights reserved. 「American Society of Hematology」, 「ASH」 and the ASH Logo are registered trademarks of the American Society of Hematology.